Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: I...
Saved in:
Main Authors: | Maria Di Pietrantonio (Author), Lucia Brescini (Author), Jennifer Candi (Author), Morroni Gianluca (Author), Francesco Pallotta (Author), Sara Mazzanti (Author), Paolo Mantini (Author), Bianca Candelaresi (Author), Silvia Olivieri (Author), Francesco Ginevri (Author), Giulia Cesaretti (Author), Sefora Castelletti (Author), Emanuele Cocci (Author), Rosaria G. Polo (Author), Elisabetta Cerutti (Author), Oriana Simonetti (Author), Oscar Cirioni (Author), Marcello Tavio (Author), Andrea Giacometti (Author), Francesco Barchiesi (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
by: Lucia Brescini, et al.
Published: (2021) -
Analysis of the clinical application of ceftazidime-avibactam in China
by: Qing Wang, et al.
Published: (2022) -
Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
by: Dan Li, et al.
Published: (2021) -
Ceftazidime-avibactam induced renal disorders: past and present
by: Yanrong Shi, et al.
Published: (2024) -
In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
by: Marta Palombo, et al.
Published: (2023)